In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Sarepta Therapeutics (SRPT), with a price target of $172.00. The company’s shares closed last Wednesday at $111.00.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.6% and a 54.5% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Global Blood Therapeutics, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $203.25, an 81.9% upside from current levels. In a report issued on April 6, RBC Capital also maintained a Buy rating on the stock with a $182.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $158.81 and a one-year low of $72.06. Currently, Sarepta Therapeutics has an average volume of 907.6K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRPT in relation to earlier this year. Last month, Hans Lennart Rudolf Wigzell, a Director at SRPT sold 5,000 shares for a total of $584,450.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
